EGFR and adenocarcinoma: Considering the influences of the dominant pathological type of adenocarcinoma and most of the patients with EGFR mutations receiving EGFR-TKI targeted therapy after BM resection, we classified patients into TKI (n = 12, 100% LUAD) and non-TKI (n = 15) groups to further assess the clinical and molecular factors.